• 888集团(中国)6008

    Global
    关于888集团(中国)6008

    致力于纳米抗体创新药物研发

    关于888集团(中国)6008
    科研论文
    截止现在，888集团(中国)6008生物研发团队在具有重要影响力的期刊上发表研究论文多篇。
    2022-06-08
    Nanobody-based label-free photoelectrochemical immunoassay for highly sensitive detection of SARS-CoV-2 spike protein
    发表于:Analytica chimica acta. 2022 Jun 8;1211:339904
    查看更多内容
    2022-01-11
    Preclinical evaluation of [99mTc]Tc-labeled anti-EpCAM nanobody for EpCAM receptor expression imaging by immuno-SPECTCT
    发表于:European Journal of Nuclear Medicine and Molecular Imaging. 2022 May;49(6):1810-1821
    查看更多内容
    2021-01-31
    A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential
    发表于:MedComm (2020). 2021 Mar;2(1):101-113
    查看更多内容
    2020-10-16
    Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy
    发表于:Journal for ImmunoTherapy of Cancer. 2020 Nov;8(2):e001156
    查看更多内容
    2020-10-15
    A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade
    发表于:Biochemical and Biophysical Research Communications. 2020 Oct 15;531(2):144-151
    查看更多内容
    2020-02-15
    Evaluation of 64Cu radiolabeled anti-hPD-L1 Nb6 for positron emission tomography imaging in lung cancer tumor mice model
    发表于:Bioorganic & Medicinal Chemistry Letters. 2020 Feb 15;30(4):126915
    查看更多内容
    总计 24 1234